BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 27104893)

  • 21. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.
    Donohue MC; Sperling RA; Petersen R; Sun CK; Weiner MW; Aisen PS;
    JAMA; 2017 Jun; 317(22):2305-2316. PubMed ID: 28609533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel Computational Proxy for Characterizing Cognitive Reserve in Alzheimer's Disease.
    Zhang Y; Hao Y; Li L; Xia K; Wu G;
    J Alzheimers Dis; 2020; 78(3):1217-1228. PubMed ID: 33252088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.
    Vos SJ; Xiong C; Visser PJ; Jasielec MS; Hassenstab J; Grant EA; Cairns NJ; Morris JC; Holtzman DM; Fagan AM
    Lancet Neurol; 2013 Oct; 12(10):957-65. PubMed ID: 24012374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.
    Koppara A; Wolfsgruber S; Kleineidam L; Schmidtke K; Frölich L; Kurz A; Schulz S; Hampel H; Heuser I; Peters O; Reischies FM; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Rüther E; Henn F; Wiltfang J; Maier W; Jessen F; Kornhuber J; Wagner M
    J Alzheimers Dis; 2016; 49(2):547-60. PubMed ID: 26484902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
    Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
    Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
    Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease.
    Liguori C; Stefani A; Sancesario G; Sancesario GM; Marciani MG; Pierantozzi M
    J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):655-9. PubMed ID: 25121572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How the cognitive reserve interacts with β-amyloid deposition in mitigating FDG metabolism: An observational study.
    Carapelle E; Serra L; Modoni S; Falcone M; Caltagirone C; Bozzali M; Specchio LM; Avolio C
    Medicine (Baltimore); 2017 Apr; 96(16):e5876. PubMed ID: 28422821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuropsychiatric Symptoms and Alzheimer Disease Biomarkers Independently Predict Progression to Incident Cognitive Impairment.
    Babulal GM; Chen L; Murphy SA; Doherty JM; Johnson AM; Morris JC
    Am J Geriatr Psychiatry; 2023 Dec; 31(12):1190-1199. PubMed ID: 37544835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
    Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.
    Niemantsverdriet E; Goossens J; Struyfs H; Martin JJ; Goeman J; De Deyn PP; Vanderstichele H; Engelborghs S
    J Alzheimers Dis; 2016; 51(1):97-106. PubMed ID: 26836187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Critical Comparison of Different Biomarkers for Alzheimer's Disease in a Clinical Setting.
    Weise D; Tiepolt S; Awissus C; Hoffmann KT; Lobsien D; Kaiser T; Barthel H; Sabri O; Gertz HJ
    J Alzheimers Dis; 2015; 48(2):425-32. PubMed ID: 26402006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The balance between cognitive reserve and brain imaging biomarkers of cerebrovascular and Alzheimer's diseases.
    Murray AD; Staff RT; McNeil CJ; Salarirad S; Ahearn TS; Mustafa N; Whalley LJ
    Brain; 2011 Dec; 134(Pt 12):3687-96. PubMed ID: 22102649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
    Stomrud E; Hansson O; Zetterberg H; Blennow K; Minthon L; Londos E
    Arch Neurol; 2010 Feb; 67(2):217-23. PubMed ID: 20142530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
    Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S
    J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Network-Based Substrate of Cognitive Reserve in Alzheimer's Disease.
    Serra L; Mancini M; Cercignani M; Di Domenico C; Spanò B; Giulietti G; Koch G; Marra C; Bozzali M
    J Alzheimers Dis; 2017; 55(1):421-430. PubMed ID: 27662319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.